Chinese new endocrine drug developer Visen Pharma announced the completion of US$150 million in Series B financing, led by Sequoia China Fund.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
